XTX Topco Ltd Increases Stake in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

XTX Topco Ltd increased its holdings in shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX - Free Report) by 47.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 182,888 shares of the company's stock after acquiring an additional 58,587 shares during the quarter. XTX Topco Ltd owned about 0.19% of Poseida Therapeutics worth $523,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in PSTX. Marshall Wace LLP acquired a new stake in shares of Poseida Therapeutics during the 2nd quarter worth approximately $31,000. Rothschild Investment LLC purchased a new stake in Poseida Therapeutics in the second quarter valued at approximately $35,000. Principal Financial Group Inc. purchased a new position in Poseida Therapeutics in the second quarter worth $35,000. Intech Investment Management LLC bought a new position in Poseida Therapeutics in the third quarter valued at $46,000. Finally, Mackenzie Financial Corp purchased a new stake in Poseida Therapeutics during the second quarter valued at about $51,000. Institutional investors own 46.87% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on PSTX. HC Wainwright restated a "neutral" rating and issued a $9.00 target price (down previously from $20.00) on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. William Blair restated a "market perform" rating on shares of Poseida Therapeutics in a report on Tuesday, November 26th. BTIG Research reiterated a "neutral" rating on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. Cantor Fitzgerald lowered shares of Poseida Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, November 26th. Finally, Piper Sandler lowered Poseida Therapeutics from an "overweight" rating to a "neutral" rating and set a $10.00 price target on the stock. in a research report on Monday, December 2nd. Five equities research analysts have rated the stock with a hold rating, According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $9.50.

Insiders Place Their Bets

In other Poseida Therapeutics news, Chairman Mark J. Gergen sold 30,000 shares of the stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $9.46, for a total transaction of $283,800.00. Following the completion of the transaction, the chairman now owns 651,291 shares of the company's stock, valued at $6,161,212.86. This represents a 4.40 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.90% of the company's stock.

Poseida Therapeutics Stock Performance

Shares of NASDAQ:PSTX traded up $0.01 during midday trading on Friday, reaching $9.51. 583,473 shares of the company's stock traded hands, compared to its average volume of 729,787. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.20 and a current ratio of 3.20. The stock has a 50 day moving average of $4.57 and a 200 day moving average of $3.54. Poseida Therapeutics, Inc. has a one year low of $1.87 and a one year high of $9.58. The company has a market cap of $929.83 million, a price-to-earnings ratio of -15.10 and a beta of 1.64.

Poseida Therapeutics Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.